Neuro-Oncology Reviews
Volume
26 Number 21
30 September 2024
Home > Publications > Neuro-Oncology Reviews > Volume 26, Year 2024 > Number 21, 30 September
Malik H, Hudaib M, Rehman A.
Vorasidenib-
A Paradigm Shift in IDH1- or IDH2-Mutant Low-Grade Glioma
Treatment.
J
Pak Med Assoc. 2024 Sep 21;74(10):1912-1913. doi:
10.47391/JPMA.20428. PMID:
39407401. Perspective. ˍ
Saqib M, Zahoor A, Rahib A, Shamim A, Mumtaz H.
Clinical
and translational advances in primary brain tumor therapy with a
focus on glioblastoma-A comprehensive review of the literature.
World
Neurosurg X. 2024 Sep 21;24:100399. doi:
10.1016/j.wnsx.2024.100399.
PMID:
39386927. Review. ˍ
Landry AP, Yefet LS, Wang JZ, Zadeh G, Nassiri F.
Methylation
profiling in the contemporary management of meningioma.
J
Neurooncol. 2024 Sep 22. doi:
10.1007/s11060-024-04825-w. PMID:
39306649. Review˰ ˍ
Le Guillou Horn XM, Lecellier F, Giraud C, Naudin M, Fayolle P,
Thomarat C, Fernandez-Maloigne C, Guillevin R.
From
Voxel to Gene: A Scoping Review on MRI Radiogenomics' Artificial
Intelligence Predictions in Adult Gliomas and Glioblastomas-The
Promise of Virtual Biopsy?
Biomedicines.
2024 Sep 23;12(9):2156. doi:
10.3390/biomedicines12092156. PMID:
39335670. Review. ˍ
Liu M, Li T, Zhao M, Qian C, Wang R, Liu L, Xiao Y, Xiao H, Tang
X, Liu H.
Nanoradiosensitizers in
glioblastoma treatment: recent advances and future perspectives.
Nanomedicine
(Lond). 2024 Sep 23;19(26):2229-2249. doi:
10.1080/17435889.2024.2395238. PMID:
39311492. Review˰ ˍ
Awuah WA, Ben-Jaafar A, Karkhanis S, Nkrumah-Boateng PA, Kong JSH,
Mannan KM, Shet V, Imran S, Bone M, Boye ANA, Ranganathan S, Shah
MH, Abdul-Rahman T, Atallah O.
Cancer
stem cells in meningiomas: novel insights and therapeutic
implications.
Clin
Transl Oncol. 2024 Sep 24. doi:
10.1007/s12094-024-03728-6. PMID: 39316249. Review.
ˍ
Ganguly K, Adhikary K, Acharjee A, Acharjee P, Trigun SK, Mutlaq
AS, Ashique S, Yasmin S, Alshahrani AM, Ansari MY.
Biological
significance and pathophysiological role of Matrix
Metalloproteinases in the Central Nervous System.
Int
J Biol Macromol. 2024 Sep 24;280(Pt 3):135967. doi:
10.1016/j.ijbiomac.2024.135967. PMID:
39322129. Review˰ ˍ
Pathikonda S, Amirmahani F, Mathew D, Muthukrishnan SD.
Histone
acetyltransferases as promising therapeutic targets in
glioblastoma resistance.
Cancer
Lett. 2024 Sep 24;604:217269. doi:
10.1016/j.canlet.2024.217269. PMID:
39326554. Review. ˍ
Viswanathan A, Brahma N, S V.
Transforming
brain cancer therapeutics: unlocking the power of blood-brain
barrier-targeting strategies for superior treatment outcomes and
precision medicine.
Neurosurg
Rev. 2024 Sep 24;47(1):673. doi:
10.1007/s10143-024-02873-4. PMID:
39316196. Review. ˍ
Cao S, Wei Y, Yue Y, Wang D, Yang J, Xiong A, Zeng H.
Mapping
the evolution and research landscape of ferroptosis-targeted
nanomedicine: insights from a scientometric analysis.
Front
Pharmacol. 2024 Sep 25;15:1477938. doi:
10.3389/fphar.2024.1477938. PMID:
39386034. Bibliometric analysis. ˍ
Gonzales CN, Negussie MB, Krishna S, Ambati VS, Hervey-Jumper SL.
Malignant glioma remodeling of
neuronal circuits: therapeutic opportunities and repurposing of
antiepileptic drugs.
Trends
Cancer. 2024 Sep 25:S2405-8033(24)00192-4. doi:
10.1016/j.trecan.2024.09.003. PMID:
39327186. Review. ˍ
Dadario NB, Boyett DM, Teasley DE, Chabot PJ, Winans NJ,
Argenziano MG, Sperring CP, Canoll P, Bruce JN.
Unveiling
the Inflammatory Landscape of Recurrent Glioblastoma through
Histological-Based Assessments.
Cancers
(Basel). 2024 Sep 26;16(19):3283. doi:
10.3390/cancers16193283. PMID:
39409905. Review. ˍ
Meng X, Tian L, Cai J.
Editorial:
Insights and implications of mechanisms shaping glioma immune
landscape, immunotherapy resistance, and relevant translational
research.
Front
Oncol. 2024 Sep 26;14:1485761. doi:
10.3389/fonc.2024.1485761. PMID:
39391240. Editorial. ˍ
Nader NE, Frederico SC, Miller T, Huq S, Zhang X, Kohanbash G,
Hadjipanayis CG.
Barriers to T Cell
Functionality in the Glioblastoma Microenvironment.
Cancers
(Basel). 2024 Sep 26;16(19):3273. doi:
10.3390/cancers16193273. PMID:
39409893. Review. ˍ
Varela ML, Comba A, Faisal SM, Argento A, Peña Aguelo JA,
Candolfi M, Castro MG, Lowenstein PR.
Cell
and gene therapy in neuro-oncology.
Handb
Clin Neurol. 2024 Sep 26;205:297-315. doi:
10.1016/B978-0-323-90120-8.00009-5. PMID:
39341660. Review. ˍ
Demaliaj D, Gardner SL.
Novel
therapies for pediatric low grade glioma.
Curr
Opin Neurol. 2024 Sep 27. doi:
10.1097/WCO.0000000000001319. PMID:
39324939. Review. ˍ
Hajikarimloo B, Hasanzade A, Sabbagh Alvani M, Habibi MA.
Application of bevacizumab in the
management of meningiomas: a systematic review and meta-analysis.
Neurosurg
Rev. 2024 Sep 27;47(1):692. doi:
10.1007/s10143-024-02889-w. PMID:
39327340. Review˰ ˍ
Jiacheng D, Jiayue C, Ying G, Shaohua W, Wenhui L, Xinyu H.
Research progress and challenges of
the PD-1/PD-L1 axis in gliomas.
Cell
Biosci. 2024 Sep 27;14(1):123. doi:
10.1186/s13578-024-01305-6. PMID:
39334448. Review. ˍ
Tapescu I, Madsen PJ, Lowenstein PR, Castro MG, Bagley SJ, Fan Y,
Brem S.
The transformative potential
of mRNA vaccines for glioblastoma and human cancer: technological
advances and translation to clinical trials.
Front
Oncol. 2024 Sep 27;14:1454370. doi:
10.3389/fonc.2024.1454370. PMID:
39399167. Review. ˍ
Mittelbronn M.
Neurooncology: 2024
update.
Free
Neuropathol. 2024 Sep 27;4:21. doi:
10.17879/freeneuropathology-2024-5809. PMID:
39385753. Review. ˍ
Verly G, Bresciani L, Delfino T, Nascimento M, Magill ST, Galvão
GDF.
Surgery alone versus surgery plus
adjuvant radiotherapy for WHO grade 2 meningioma: meta-analysis of
reconstructed time-to-event data.
Neurosurg
Rev. 2024 Sep 28;47(1):702. doi:
10.1007/s10143-024-02946-4. PMID:
39333271. Meta-analysis˰
ˍ
Lizunou Y, Potthoff AL, Schäfer N, Waha A, Borger V,
Herrlinger U, Vatter H, Schuss P, Schneider M.
Cerebellar
glioblastoma in adults: a comparative single-center matched pair
analysis and systematic review of the literature.
J
Cancer Res Clin Oncol. 2024 Sep 28;150(9):432. doi:
10.1007/s00432-024-05959-0. PMID:
39340649. Observational study; Review. ˍ
Markouli M, Papachristou A, Politis A, Boviatsis E, Piperi C.
Emerging Role of the Slit/Roundabout
(Robo) Signaling Pathway in Glioma Pathogenesis and Potential
Therapeutic Options.
Biomolecules.
2024 Sep 29;14(10):1231. doi:
10.3390/biom14101231. PMID:
39456164. Review. ˍ
Mercado NB, Real JN, Kaiserman J, Panagioti E, Cook CH, Lawler SE.
Clinical implications of
cytomegalovirus in glioblastoma progression and therapy.
NPJ
Precis Oncol. 2024 Sep 29;8(1):213. doi:
10.1038/s41698-024-00709-4. PMID:
39343770. Review. ˍ
Ahmed M, Sieben A, Van Genechten T, Libbrecht S, Gilis N, De
Praeter M, Fricx C, Calò P, Van Campenhout C, D'Haene N,
Witte O, Kempen LCV, Lammens M, Salmon I, Lebrun L.
Rare
Oncogenic Fusions in Pediatric Central Nervous System Tumors: A
Case Series and Literature Review.
Cancers
(Basel). 2024 Sep 30;16(19):3344. doi:
10.3390/cancers16193344. PMID:
39409964. Review. ˍ
Rudà R, Pellerino A, Soffietti R.
Blood
and cerebrospinal fluid biomarkers in neuro-oncology.
Curr
Opin Neurol. 2024 Sep 30. doi:
10.1097/WCO.0000000000001317. PMID:
39329301. Review. ˍ
Stępka J, Dotka M, Kosiński M, Suchecki P, Hobot M,
Piotrowski I.
The Role of Systemic
Therapies in the Treatment of Grades 1-4 Gliomas.
Cureus.
2024 Sep 30;16(9):e70532. doi:
10.7759/cureus.70532. PMID:
39439623. Review. ˍ
Valerius AR, Webb LM, Thomsen A, Lehrer EJ, Breen WG, Campian JL,
Riviere-Cazaux C, Burns TC, Sener U.
Review
of Novel Surgical, Radiation, and Systemic Therapies and Clinical
Trials in Glioblastoma.
Int
J Mol Sci. 2024 Sep 30;25(19):10570. doi:
10.3390/ijms251910570. PMID:
39408897. Review. ˍ
Wu J, Wang N.
Current progress of
anti-PD-1/PDL1 immunotherapy for glioblastoma (Review).
Mol
Med Rep. 2024 Sep 30;30(6):221. doi:
10.3892/mmr.2024.13344. PMID:
39364736. Review. ˍ